Loading organizations...
§ Private Profile · Cambridge, MA, USA
Clinical-stage biopharmaceutical company developing lymph node-targeting immunotherapies for mKRAS-driven and aggressive cancers.
Based in Boston, Massachusetts, Elicio Therapeutics is a clinical-stage biopharmaceutical company developing lymph node-targeting Amphiphile technology to create novel immunotherapies for aggressive cancers. The pre-revenue biotechnology firm focuses on engineering specialized immunomodulators, adjuvants, and therapeutic vaccines, primarily advancing its lead clinical candidate, ELI-002, which specifically targets mKRAS-driven tumors. Operating without current commercial product revenues, the enterprise funds its oncology research pipeline through a combination of private and public market equity financings, strategic partnering transactions, and government grants. The organization's strategic direction and clinical development are guided by key industry figures including Chief Executive Officer Robert Connelly, who joined the firm in October 2018, Board Chairman Julian Adams, and Board Director Jay Venkatesan. Elicio Therapeutics was originally established by co-founder Darrell Irvine to harness the body's lymph nodes for enhanced immune responses against aggressive solid tumors.
Elicio Therapeutics has raised $115.8M across 4 funding rounds.
Elicio Therapeutics has raised $115.8M in total across 4 funding rounds.
Elicio Therapeutics has raised $115.8M across 4 funding rounds. Most recently, it raised $7.0M Other Equity in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 25, 2023 | $7M Venture Round | Gkcc | — | Announced |
| Sep 20, 2022 | $2.8M Grant | Jackie Casey | — | Announced |
| Feb 17, 2021 | $73M Series B | — | — | Announced |
| Oct 2, 2019 | $33M Series B | — | Efung Capital, Livzon Pharmaceutical Group | Announced |
Elicio Therapeutics has raised $115.8M in total across 4 funding rounds.
Elicio Therapeutics's investors include GKCC, Jackie Casey, Efung Capital, Livzon Pharmaceutical Group.